IL22RA2抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue lysate, Primary antibody: P08436(IL22RA2 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P08436(IL22RA2 Antibody) at dilution 1/130. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P08436(IL22RA2 Antibody) at dilution 1/130. (Original magnification: ×200)    

  
  

IL22RA2. also known as interleukin-22 receptor subunit alpha-2 or IL-22 binding protein (IL-22BP), is a soluble receptor homolog that modulates the activity of IL-22. a cytokine involved in inflammatory responses and tissue repair. Unlike the membrane-bound IL-22 receptor complex (IL-22RA1/IL-10Rβ), IL22RA2 lacks a transmembrane domain and functions as a decoy receptor. It binds IL-22 with high affinity, competitively inhibiting its interaction with the signaling receptor, thereby attenuating IL-22-mediated pathways such as STAT3 activation. This regulatory mechanism positions IL22RA2 as a critical player in balancing IL-22's roles in mucosal immunity, epithelial homeostasis, and pathological inflammation.

Antibodies targeting IL22RA2 are valuable tools for studying its expression, distribution, and interaction dynamics with IL-22. They enable researchers to explore IL22RA2's involvement in diseases like psoriasis, inflammatory bowel disease (IBD), rheumatoid arthritis, and cancer, where IL-22 signaling is dysregulated. Therapeutic antibodies against IL22RA2 are under investigation to either block its decoy activity (enhancing IL-22's protective effects) or stabilize its binding to IL-22 (reducing excessive inflammation). Such strategies hold potential for treating conditions characterized by IL-22 imbalance. However, the dual role of IL-22 in both tissue repair and inflammation necessitates careful evaluation of antibody-based interventions to avoid unintended outcomes. Current research focuses on optimizing specificity and pharmacokinetics to advance these antibodies toward clinical applications.